title: [Treatment of spasticity with the intrathecal administration of baclofen].
abstract: Direct intrathecal administration of baclofen in the treatment of severe spasticity was proposed in 1984 by Richard Penn with the objective to carry out a selective spinal distribution of the active principle thus avoiding supraspinal side effects. We presented our first results at the French Language Association of Neurosurgery in 1985 within the framework of a report on "Functional neurosurgery of cerebral palsy" (Neurochirurgie, 1985, 31 (suppl 1): 1-118). This study aims to specify the selection criteria and current indications of this method for the treatment of severe chronic diffused spasticity of spinal and cerebral origin in adults and in children. This report relates to our experience concerning 60 patients (10 children) that benefit from the use of a totally implantable system for chronic administration. The total follow-up of all patients was 48 months (from 3 to 140 months). The initial effective daily amount of baclofen was 156 micrograms/24 hours and progressed in time to reach in the long run 280 micrograms/24 hours, with a very broad interindividual variability from 36 to 1050 micrograms/24 hours. All the patients benefited from a reduction in muscular hypertonicity as well as painful muscular spasms. On the other hand, the functional improvement was very variable from one patient to another and depended primarily on the initial clinical state and the etiology of the spasticity. The results observed were more significant in post-traumatic paraplegia than those secondary to demyelination disease even if they were stabilized with regard to spasticity of spinal origin. This mode of administration currently plays a significant role in the treatment of spasticity of cerebral origin, in particular in children presenting a motor disorder of cerebral origin with spastic prevalence. The current limitations of this type of treatment are technical because of the frequent catheter malfunctions, but are due essentially to the importance and constraint of the multi-disciplinary organization needed for the out-patient follow-up.
authors.affiliation: Service de Neurochirurgie, Hôpital de Rangueil, Toulouse.
authors.forename: Y
authors.initials: Y
authors.lastname: Lazorthes
authors.forename: B
authors.initials: B
authors.lastname: Sallerin
authors.forename: J C
authors.initials: JC
authors.lastname: Verdié
authors.forename: J
authors.initials: J
authors.lastname: Casaux
authors.forename: F
authors.initials: F
authors.lastname: Caraoué
authors.forename: J C
authors.initials: JC
authors.lastname: Sol
mesh_terms: D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005500:Follow-Up Studies; D006801:Humans; D007278:Injections, Spinal; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009125:Muscle Relaxants, Central; D001418:Baclofen
vernacular_title: Traitement de la spasticité par administration intra-thécale chronique de baclofène.